The multicultural and multilinguistic landscape in Asia poses interesting challenges in the assessment and improvement of Health-Related Quality of Life (HRQoL) in Asian patients with systemic lupus erythematosus (SLE). This article highlights some of these challenges and addresses the issue of how to improve HRQoL of these patients by: (1) framing important concepts in HRQoL in relation to the chronic relapsing nature and multisystem involvement in this condition; (2) discussing ways to improve measurement of HRQoL of SLE patients in Asia by reviewing existing HRQoL instruments (both generic (i.e. the SF-36) and disease-specific (i.e. the L-QoL, LupusQoL, SLEQoL and SLE Symptom Checklist)) and item banking; and (3) discussing approaches to improving HRQoL in SLE.
Navarra SV, King JOAn overview of clinical manifestations and survival of systemic lupus erythematosus patients in Asia. APLAR J Rheumatol2006; 9: 336-341.
2.
Thumboo J., Strand V.Health-related quality of life in patients with systemic lupus erythematosus: an update. Ann Acad Med Singapore2007; 36: 115-122.
3.
Food and Drug Administration.Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. [updated 2009 Dec, accessed 2010 June 26], available from ttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf
4.
Last JMA dictionary of epidemiology. New York: Oxford University Press; 1995.
5.
Fayers P., Machin D.Quality of Life: The Assessment, Analysis and Interpretation of Patient-reported Outcomes, 2nd Edition. Hoboken, NJ: John Wiley & Sons, 2007.
6.
Thumboo J., Chan SP, Machin D., et al. Measuring health related quality of life in singapore: normal values for the English & Chinese SF-36 health survey. Ann Acad Med Singapore2002; 31: 366-374.
7.
Zheng Y., Ye DQ, Pan HF, et al. Influence of social support on health-related quality of life in patients with systemic lupus erythematosus. Clin Rheumatol2009; 28: 265-269.
8.
Mok CC, Ho LY, Cheung MY, Yu KL, To CHEffect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol2009; 38: 121-127.
9.
McElhone K., Abbott J., Teh LSA review of health related quality of life in systemic lupus erythematosus . Lupus2006; 15: 633-643.
10.
Strand V., Crawford B.Improvement in health-related quality of life in patients with SLE following sustained reductions in antidsDNA antibodies. Expert Rev Pharmacoecon Outcomes Res2005; 5: 317-326.
11.
Strand V.Issues in drug development in SLE: clinical trial design, outcome measures and biomarkers. In: Wallace DJ, Hahn BH (eds), Dubois’ lupus erythematosus . Los Angeles: Williams & Wilkins;1997.
12.
Strand V., Petri M., Buyon J., et al. Baseline data from 5 randomized controlled trials (RCTs) demonstrate that systemic lupus erythematosus (SLE) impacts all domains of health-related qualty of life (HRQoL). Arthritis Rheum2006 ; 54: S277.
13.
Seawell AH, Danoff-Burg S.Psychosocial research on systemic lupus erythematosus: a literature review . Lupus2004; 13: 891-899.
14.
Yee CS, McElhone K., Teh LS, Gordon C.Assessment of disease activity and quality of life in systemic lupus erythematosus - new aspects. Best Pract Res Clin Rheumatol2009; 23: 457-467.
15.
Gordon C., Clarke AEQuality of life and economic evaluation in SLE clinical trials. Lupus1999; 8: 645-654.
16.
Thumboo J.Measuring functional status in patients with systemic lupus erythematosus . APLAR J Rheumatol2003; 6: 184-187.
17.
Strand V., Gladman D., Issenberg D., Petri M., Smolen J., Tugwell P.Outcome measures to be used in clinical trials in systemic lupus erythematosus . J Rheumatol1999; 26: 490-497.
18.
Gladman DD, Urowitz MB, Gough J., MacKinnon A.Fibromyalgia is a major contributor to quality of life in lupus. J Rheumatol1997; 24: 2145-2148.
19.
Dussán KB, Magder L., Brodsky RA, Jones RJ, Petri M.High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures . Lupus2008; 17: 1079-1085.
20.
Tse KC, Tang CS, Lio WI, Lam MF, Chan TMQuality of life comparison between corticosteroid- and- mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritis. Lupus2006; 15: 371-9.
21.
Strand V., Gladman D., Isenberg D., Petri M., Smolen J., Tugwell P.Endpoints: consensus recommendations from OMERACT IV: Outcome Measures in Rheumatology. Lupus2000; 9: 322-327.
22.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).Guidance for industry: systemic lupus erythematosus - developing drugs for treatment page 12. [2010 June, accessed 2010 June 26] available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf
23.
Bertsias G. , Gordon C., Boumpas DTClinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus2008; 17: 437-442.
24.
Strand V., Crawford B., Petri M., et al. Patients with active systemic lupus erythematosus (SLE) treated with belimumab improve health-related quality of life (HRQoL) in a randomized controlled trial (RCT). Arthritis Rheum2006 ; 54: S277.
25.
Strand V., Crawford B., Petri M., et al. Therapeutic responses reflecting a reduction in SELENA SLEDAI score are associated with a stabilization or improvement in health-related quality of life (HRQoL). Arthritis Rheum2006 ; 54: S278.
26.
Leong KP, Kong KO, Thong BY, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatol ( Oxf) 2005; 44: 1267-1276.
27.
McElhone K. , Abbott J., Shelmerdine J., et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum2007; 57: 972-979.
28.
Grootscholten C., Ligtenberg G., Derksen RH, et al. Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Qual Life Res2003; 12: 635-644.
29.
Doward LC, McKenna SP, Whalley D., et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis2009; 68: 196-200.
30.
Bauernfeind B., Aringer M., Prodinger B., et al. Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. Arthritis Rheum2009; 61: 21-28.
31.
Herdman M., Fox-Rushby J., Badia X.A model of equivalence in the cultural adaptation of HRQoL instruments: the universalist approach. Qual Life Res1998 ; 7: 323-35.
32.
Stewart AL, Nápoles-Springer A.Health-related quality-of-life assessments in diverse population groups in the United States. Med Care2000; 38: 102-124.
33.
Wee HL, Cheung YB, Fong KY, Luo N., Machin D., Thumboo J.Are English- and Chinese-language versions of the SF-6D equivalent? A comparison from a population-based study. Clin Ther2004 ; 26: 1137-1148.
34.
Kong KO, Ho HJ, Howe HS, et al. Cross-cultural adaptation of the Systemic Lupus Erythematosus Quality of Life Questionnaire into Chinese. Arthritis Rheum2007; 57: 980-985.
35.
Tam LS, Wong A., Mok VC, et al. The relationship between neuropsychiatric, clinical, and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus . J Rheumatol2008; 35: 1038-1045.
36.
Mok CC, Ho LY, Cheung MY, Yu KL, To CHEffect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol2009; 38: 121-127.
37.
Kumar K., Gordon C., Toescu1 V., et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatol2008; 47: 690-697.
38.
Sung YK, Oh KT, Kwak EJ, et al. Health-related quality of life in Korean patients with systemic lupus erythematosus. J Korean Rheum Assoc2002; 9: S84-S95.
39.
Shahrir MS, Fauzi AR, Kong NCT, Rizal AM, Arina MZDisease acitivity and general health status in Malaysian systemic lupus erythematosus patients. Int Med J2005 ; 4.
40.
Thumboo J., Feng PH, Boey ML, Soh CH, Thio ST, Fong KYValidation of the Chinese SF-36 for quality of life assessment in patients with systemic lupus erythematosus. Lupus2000 ; 9: 708-712.
41.
QualityMetric.‘Surveys and translations available’http://www.qualitymetric.com/WhatWeDo/LanguageTranslations/SurveysandTranslationsAvailable/tabid/215/Default.aspx# (2009 , accessed June 2010).
42.
Fortin PR, Abrahamowicz M., Neville C., et al. Impact of disease activity and cumulative damage on the health of lupus patients. Lupus1998; 7: 101-107.
43.
Thumboo J., Fong KY, Chan SP, et al. A prospective study of factors affecting quality of life insystemic lupus erythematosus. J Rheumatol2000; 27: 1414-1420.
44.
Gladman DDA novel, disease-specific quality-of-life instrument for patients with SLE . Nat Clin Pract Rheumatol2006; 2: 132-133. 45 Fortin PR, Abrahamowicz M., Neville C., et al. Impact of disease activity and cumulative damage on the health of lupus patients . Lupus1998; 7: 101-107.
